Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13
|
|
- Scarlett Evans
- 5 years ago
- Views:
Transcription
1 Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13 Mark Cunningham,MD Director, Hematology Laboratory Department of Pathology University of Kansas Medical Center College of American Pathologists Materials are used with the permission of Mark Cunningham, MD, FCAP. 1
2 Course Objectives Review the definition, diagnosis, classification, pathophysiology, and treatment of TTP Discuss the role of ADAMTS-13 in the pathophysiology, diagnosis, classification, and treatment of TTP 2
3 TTP and ADAMTS-13 Lecture Outline I. Review of TTP II. Role of ADAMTS-13 in TTP A. Laboratory assays B. Diagnosis C. Classification D. Treatment III. Case Studies IV. Summary V. Pearls of Pathology 3
4 TTP: Definition Microvascular occlusive syndrome Systemic platelet aggregation Multiple organ ischemia Severe thrombocytopenia Red cell fragmentation 4
5 TTP: Definition Purpura Schistocytes Thrombocytopenia Microvascular Thrombosis 5
6 TTP: Diagnosis Diagnostic Criteria 1. Microangiopathic hemolysis - elevated LDH, schistocytes on blood smear 2. Thrombocytopenia 3. Fever, renal failure, and neurologic manifestations are NOT required for diagnosis 4. Exclusion of similar disorders - hemolytic uremic syndrome - disseminated intravascular coagulation - malignant hypertension - eclampsia - vasculitis - HEELP syndrome - Evans syndrome 6
7 TTP: Diagnosis Disorders Mimicking TTP Disorder TTP HUS DIC Malignant hypertension Eclampsia Vasculitis Mechanism ADAMTS-13 deficiency Shiga toxin ST1 or ST2 Excess tissue factor High blood pressure Unknown vasoconstrictor Hypersensitivity reaction Treatment Plasma exchange Supportive Antibiotics, chemotherapy, deliver placenta, etc. Anti-hypertensives Deliver placenta Immunosuppressives 7
8 TTP: Classification Classification Frequency Age of Onset Clinical Course Inherited 10% Infancy Recurrent episodes Childhood (regular intervals) Acquired 90% Adult Single episode, or Recurrent episodes (irregular intervals) 8
9 TTP: Classification Acquired TTP Idiopathic Drugs Autoimmune disorders Pregnancy Infection Stem cell transplant Malignancy 9
10 TTP: Classification Drug Associated TTP Cardiovascular - quinine Immunosuppressive - cyclosporine A, tacrolimus (FK506) Chemotherapy - mitomycin C, carmustine, pentostatin Antithrombotic - ticlopidine (Ticlid), clopidogrel (Plavix) 10
11 TTP: Pathophysiology Von Willebrand Factor (VWF) Synthesis - endothelial cells and megakaryocytes Primary structure - single polypeptide (MW = 280 kd) - several repetitive domains (A1-3, B, C1-2, D1-4) Quaternary structure - monomers disulfide linked into multimers - varying multimer size (600 to 20,000 kd) 11
12 TTP: Pathophysiology Von Willebrand Factor (VWF) Function - platelet adhesion (collagen, GP Ib/V/IX) - platelet aggregation (GP IIb/IIIa - high shear) - factor VIII carrier protein Cell Biology - endothelial cells produce unusually large von Willebrand factor multimers (ULVWF) - ULVWF mediate platelet aggregation (high shear stress) - ULVWF are absent from normal plasma 12
13 TTP: Pathophysiology VWF Structure and Function ULVWF Multimers Multimer Structure Platelet Adhesion Factor VIII Carrier Protein 13
14 TTP: Pathophysiology Von Willebrand Factor (VWF) Abnormality in TTP - ULVWF multimers persist in plasma - ULVWF mediate spontaneous platelet aggregation and thrombosis in arterial microcirculation (high shear stress) 14
15 TTP: Pathophysiology ULVWF Multimers Moake JL. Sem Hematol 41: 4-14,
16 TTP: Pathophysiology Acronym ADAMTS-13 - a disintegrin and metalloprotease with thrombospondin - like domains - ADAMTS family (18 members) Synonym - VWF cleaving protease Synthesis - Liver perisinusoidal cells 16
17 TTP: Pathophysiology ADAMTS-13 Primary Structure - Single polypeptide (180kD) - Multiple distinct domains Gene - 9q34 Function - Specific proteolytic activity against VWF Cofactors - Zinc and calcium 17
18 TTP: Pathophysiology ADAMTS-13 Structure and Function Moake JL. Sem Hematol 41: 4-14, 2004 Plaimauer B et al. Sem Hematol 41: 24-33,
19 TTP: Pathophysiology ADAMTS-13 Abnormality in TTP - Decreased activity due to gene mutation (inherited) - Decreased activity due to autoantibody (acquired) 19
20 TTP: Pathophysiology Moake JL. Sem Hematol 41: 4-14,
21 ADAMTS-13: Laboratory Assays General Principle Add patient plasma to source of VWF Use special buffer conditions - Denaturant (urea, GnHCl) - Barium chloride - Alkaline ph - Low ionic strength - Prolonged incubation (2-24 Hrs) Measure decrease in substrate or increase in product: electrophoresis, VWF function, VWF antigen Compare patient data to standard curve prepared using dilutions of pooled normal plasma EDTA irreversibly inhibits ADAMTS-13 21
22 ADAMTS-13: Laboratory Assays NHP ADAMTS-13 Activity (%) Electrophoresis ELISA: Type III Collagen Binding Gerritsen et al. Thromb Haemost 82: ,
23 ADAMTS-13: Laboratory Assays Assay Method Principle Reference Range Literature Citation Electrophoresis ULVWF multimers Decreased substrate > 50% Furlan et al, 1997 Electrophoresis VWF fragmentation dimers Increased product 68% - 126% Tsai et al, 1998 Functional Collagen binding activity Decreased substrate 29% - 119% Gerritsen et al, 1999 Functional Ristocetin cofactor activity Decreased substrate 52% - 134% Bohm et al, 2002 Antigenic ULVWF multimers Decreased substrate 44% - 178% Obert et al,
24 ADAMTS-13: TTP Diagnosis Sensitivity of ADAMTS-13 Deficiency in TTP Highly Variable 15% - 100% (6 studies) Marques MB et al. Am J Clin Pathol 121(Suppl): S89-S96,
25 ADAMTS-13: TTP Diagnosis Sensitivity of ADAMTS-13 Deficiency in TTP TTP Classification Inherited Acquired - Idiopathic Acquired - Autoimmune Acquired - Malignancy Acquired - Stem Cell Tx Acquired - Pregnancy Acquired Ticlopidine/ Sildenafil ADAMTS-13 Deficiency (<5%) 100% (33/33) 52% (56/108) 23% (10/43) 5% (1/21) 5% (1/19) 56% (5/9) 100% (8/8) ADAMTS-13 Inhibitor 0% (0/33) 79% (54/68) 48% (13/27) 5% (1/21) 5% (1/19) 44% (4/9) 100% (8/8) Matsumoto M, et al. Sem. Hematol. 41(1): 68-74,
26 ADAMTS-13: TTP Diagnosis Specificity of ADAMTS-13 Deficiency Clinical Condition No. of Patients ADAMTS-13 Activity, mean + SD ADAMTS-13 Activity, range Metastatic cancer 20 4% + 5% NA Acute inflammation 15 40% + 12% 15% 59% Liver cirrhosis 42 46% + 33% 6% - 146% Newborn 26 52% + 7% 25% - 118% Postoperative 24 58% + 27% 18% - 131% Pregnancy 2 nd trimester 19 64% + 34% 22% - 135% 3 rd trimester 32 64% + 15% 38% - 102% Chronic uremia 63 74% + 30% 15% - 140% Mannucci PM et al. Blood 98: , 2001 Oleksowitcz L et al. Cancer Res 59: ,
27 ADAMTS-13: TTP Diagnosis Specificity of ADAMTS-13 Deficiency Type of HUS Number ADAMTS-13 ADAMTS-13 ADAMTS-13 ADAMTS-13 < 3% 3 25% 26 50% > 50% Idiopathic 34 0% 12% 53% 35% E. Coli 0157:H7 7 0% 0% 71% 29% Mitomycin C 3 0% 33% 33% 33% Matsumoto M, et al. Sem. Hematol. 41(1): 68-74,
28 ADAMTS-13: TTP Classification ADAMTS-13 Activity > 5% ADAMTS-13 Inhibitor ND Interpretation Cannot Rule Out TTP < 5% < 5% Negative Positive Rule In TTP - hereditary if positive family history Acquired TTP - regardless of family history 28
29 ADAMTS-13: TTP Treatment TTP Classification ADAMTS-13 Activity Treatment Response Rate Inherited < 5% Plasma Infusion 100% - Every 3 to 4 weeks Acquired < 5% Plasma Exchange 83% Acquired > 5% Plasma Exchange 33% Matsumoto M, et al. Sem. Hematol. 41(1): 68-74,
30 Case Study 1 History: 4 yo girl presents with 1 week history of skin bruising and fever. Family history: Two cousins died of similar disorder Physical exam: Multiple petechiae and ecchymoses over arms, legs, trunk, and back. 30
31 Case Study 1 (Cont.) Laboratory Test Hemoglobin White blood cells Platelets Blood smear Lactate dehydrogenase Creatinine Prothrombin time Partial thromboplastin time Fibrinogen D-Dimer ADAMTS-13, activity ADAMTS-13 inhibitor Patient Result 7.2 8,000 10, schistocytes s 300 < 0.5 2% Negative Reference Range g/dl ,000 /ul 150, ,000 /ul < 1 schistocyte /HPF U/L mg/dl s s mg/dl < 0.5 mg/l 30% - 120% Negative 31
32 Case Study 1 (Cont.) Question 1. What is the diagnosis? Answer: Inherited TTP (Upshaw-Schulman syndrome) Question 2. What is the most appropriate therapy? Answer: Daily plasma exchange for initial therapy. After ADAMTS-13 result confirms diagnosis of inherited TTP, then plasma infusion (every 3-4 weeks) would be appropriate. 32
33 Case Study 2 History: 8 yo boy presents with 3 day history of bloody diarrhea and fever. Symptoms began 1 day after eating a hamburger at a local restaurant. Family history: Negative Physical exam: Negative for petechiae or bruising 33
34 Case Study 2 (Cont.) Laboratory Test Hemoglobin White blood cells Platelets Blood smear Lactate dehydrogenase Creatinine D-Dimer ADAMTS-13, activity ADAMTS-13 inhibitor E. Coli Shiga-like toxin Patient Result ,000 50,000 8 schistocytes < % Not done Positive Reference Range g/dl ,000 /ul 150, ,000 /ul < 1 schistocyte /HPF U/L mg/dl < 0.5 mg/l 30% - 120% Negative Negative 34
35 Case Study 2 (Cont.) Question 1. What is the diagnosis? Answer: Hemolytic uremic syndrome Question 2. What is the most appropriate therapy? Answer: Supportive therapy for renal failure 35
36 Case Study 3 History: 45 yo woman presents with one week history of headache, disorientation, and lethargy Past Medical History: Negative. Not taking medicines Family history: Negative Physical exam: Petechiae and ecchymoses noted on legs 36
37 Case Study 3 (Cont.) Laboratory Test Hemoglobin White blood cells Platelets Blood smear Lactate dehydrogenase Creatinine Prothrombin time Partial thromboplastin time Fibrinogen D-Dimer ADAMTS-13, activity ADAMTS-13 inhibitor Patient Result ,200 15, schistocytes s 480 < 0.5 1% Positive, 3.0 BU Reference Range g/dl ,000 /ul 150, ,000 /ul < 1 schistocyte /HPF U/L mg/dl s s mg/dl < 0.5 mg/l 30% - 120% Negative 37
38 Case Study 3 (Cont.) Question 1. What is the diagnosis? Answer: Acquired idiopathic TTP (autoimmune) Question 2. What is the most appropriate therapy? Answer: Daily plasma exchange until platelet count >150 K/uL for 2 consecutive days. Consider immunosuppressive therapy if no response or relapse (Rituximab, etc.) 38
39 Summary 1. ADAMTS-13 maintains normal hemostasis by degrading unusually large VWF multimers 2. Severe ADAMTS-13 deficiency (<5% activity) contributes to the pathogenesis of TTP 3. ADAMTS-13 deficiency due to genetic mutation is a common cause of inherited TTP 4. ADAMTS-13 autoantibodies is a common cause of acquired TTP 5. Severe ADAMTS-13 deficiency predicts a good response to plasma exchange 39
40 Pearls of Pathology Diagnosis of TTP Diagnosis of TTP is based on 3 criteria: thrombocytopenia, microangiopathic hemolysis, exclusion of similar diseases ADAMTS-13 specimen should be collected prior to plasma exchange ADAMTS-13 specimen should be collected in citrate anticoagulant, NOT EDTA 40
41 Pearls of Pathology Diagnosis of TTP Severe ADAMTS-13 deficiency (< 5% activity) - confirms diagnosis of TTP - rules out HUS Mild to moderate ADAMTS-13 deficiency (> 5% activity) is very nonspecific Normal ADAMTS-13 level DOES NOT rule out TTP 41
42 Pearls of Pathology Classification of TTP Severe ADAMTS-13 deficiency without an inhibitor, plus a family history of a TTP-like syndrome, is diagnostic of inherited TTP Severe ADAMTS-13 deficiency due to an inhibitor is diagnostic of acquired TTP 42
43 Pearls of Pathology Treatment of TTP ADAMTS-13 levels should NOT be used to determine if plasma exchange should be initiated for acquired TTP ADAMTS-13 levels should NOT be used to determine the duration of plasma exchange therapy ADAMTS-13 levels should NOT be used to predict relapse 43
* Renal insufficiencies
Thrombotic Thrombocytopenic Purpura Behzad Poopak, DCLS PhD. Tehran medical Branch Islamic Azad university bpoopak@yahoo.com Case Summary Ms. X, a 35-year year-old woman Complained of weakness, low grade
More informationDR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL
DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL Rare but fatal disease if unrecognized and untreated Incidence about 1: 1 million in the USA Female preponderance of 2:1 Part
More informationTHROMBOTIC MICROANGIOPATHY. Jun-Ki Park 7/19/11
THROMBOTIC MICROANGIOPATHY Jun-Ki Park 7/19/11 TMAs are microvascular occlusive disorders characterized by systemic or intrarenal aggregation of platelets, thrombocytopenia, and mechanical injury to erythrocytes.
More informationApproccio morfologico alle microangiopatie trombotiche
Approccio morfologico alle microangiopatie trombotiche Gina Zini Polo Oncologia e Ematologia Policlinico A. Gemelli Università Cattolica S. Cuore - Roma 1 Thrombotic microangiopathies Occlusive microangiopathic
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More informationWhat is meant by Thrombotic Microangiopathy (TMA)?
What is meant by Thrombotic Microangiopathy (TMA)? Thrombotic Microangiopathy (TMA) is a group of disorders characterized by injured endothelial cells, microangiopathic hemolytic anemia (MAHA), with its
More informationDRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)
Preamble: A confirmed diagnosis of atypical hemolytic uremic syndrome (ahus) is required for eculizumab funding. The information below is to provide clinicians with context for how a diagnosis of ahus
More informationNew insights in thrombotic microangiopathies : TTP and ahus
New insights in thrombotic microangiopathies : TTP and ahus Dr Catherine LAMBERT Hematology Cliniques universitaires Saint-Luc Catherine.lambert@uclouvain.be New insights in thrombotic microangiopathies
More informationObjectives. Thrombotic Thrombocytopenic Purpura (TTP) and ADAMTS13 Testing. Disclosure
Thrombotic Thrombocytopenic Purpura (TTP) and Testing Dong Chen MD PhD Special Coagulation Laboratory Mayo Clinic-Rochester 2018 Disclosure Chair, CAP Coagulation Resource Committee Mayo Medical Laboratory
More informationAtypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature
Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature Mouhanna Abu Ghanimeh 1, Omar Abughanimeh 1, Ayman Qasrawi 1, Abdulraheem
More informationPathology note 8 BLEEDING DISORDER
Pathology note 8 BLEEDING DISORDER Slide75 ( Types of clotting factors deficiency): Today we will talk about public public factor deficiency it could be acquired or inherited, acquired diseases are more
More informationHemolytic uremic syndrome: Investigations and management
Hemolytic uremic syndrome: Investigations and management SAWAI Toshihiro M.D., Ph.D. Department of Pediatrics, Shiga University of Medical Science Otsu, JAPAN AGENDA TMA; Thrombotic micro angiopathy STEC-HUS;
More informationLAMA SHATAT TTP, ITP, DIC
TTP, ITP, DIC Reduction in platelet number (thrombocytopenia) constitutes an important cause of generalized bleeding. A count less than 100,000 platelets/μl is generally considered to constitute thrombocytopenia.
More informationEDUCATIONAL COMMENTARY PLATELET DISORDERS
EDUCATIONAL COMMENTARY PLATELET DISORDERS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Earn
More informationLet`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016
Let`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016 Case report 20 months old girl Israeli Arab Muslim family, consanguineous marriage
More informationThrombotic thrombocytopenic purpura: a look at the future
Thrombotic thrombocytopenic purpura: a look at the future Andrea Artoni, MD Ph.D. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca Granda Ospedale Maggiore Policlinico Milan, Italy andrea.artoni@policlinico.mi.it
More informationThrombotic Thrombocytopenic
The Treatment of TTP and the Prevention of Relapses GERALD APPEL, MD Professor of Clinical Medicine Columbia University College of Physicians and Surgeons NY-Presbyterian Hospital New York, New York Thrombotic
More informationPlatelets: Thrombotic Thrombocytopenic Purpura
Platelets: Thrombotic Thrombocytopenic Purpura James N. George, J. Evan Sadler, and Bernhard Lämmle Abnormalities of plasma von Willebrand factor (VWF) have been recognized to be associated with thrombotic
More informationBleeding and Thrombotic Disorders. Kristine Krafts, M.D.
Bleeding and Thrombotic Disorders Kristine Krafts, M.D. Bleeding and Thrombotic Disorders Bleeding disorders von Willebrand disease Hemophilia A and B DIC TTP/HUS ITP Thrombotic disorders Factor V Leiden
More informationMost Common Hemostasis Consults: Thrombocytopenia
Most Common Hemostasis Consults: Thrombocytopenia Cindy Neunert, MS MSCS Assistant Professor, Pediatrics CUMC Columbia University TSHNA Meeting, April 15, 2016 Financial Disclosures No relevant financial
More informationThrombotic Thrombocytopenic Purpura and ADAMTS-13: New Insights into Pathogenesis, Diagnosis, and Therapy
Thrombotic Thrombocytopenic Purpura and ADAMTS-13: New Insights into Pathogenesis, Diagnosis, and Therapy Janis Wyrick-Glatzel, MS, MT(ASCP) (University of Nevada Las Vegas, Las Vegas, NV) DOI: 10.1309/77KRKLJW0EA75T2R
More informationThings to never miss in the office. Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC
Things to never miss in the office Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC Presenter Disclosure Faculty / Speaker s name: Brett Houston / Leonard Minuk Relationships with commercial
More informationThrombotic Thrombocytopenic Purpura From Platelet Aggregates to Plasma
Pathology Patterns Reviews Thrombotic Thrombocytopenic Purpura From Platelet Aggregates to Plasma Marisa B. Marques, MD, 1 Charles A. Mayfield, MD, PhD, 1 and Douglas P. Blackall, MD 2 Key Words: Thrombotic
More informationDr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College
Dr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College AN APPROACH TO BLEEDING DISORDERS NORMAL HEMOSTASIS After injury, 3 processes halt bleeding Vasoconstriction
More informationSome renal vascular disorders
Some renal vascular disorders Introduction Nearly all diseases of the kidney involve the renal blood vessels secondarily We will discuss: -Hypertension (arterionephrosclerosis in benign HTN & hyperplastic
More informationISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES ALDO E CELE DACCO
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CENTRO MARIO DI NEGRI RICERCHE INSTITUTE CLINICHE FOR PHARMACOLOGICAL PER LE MALATTIE RESEARCH RARE CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES
More informationBehzad Poopak, DCLS PhD
Behzad Poopak, DCLS PhD Test Report Name Age Critical Low HEMATOLOGY Activated Partial Thromboplastin Time, Plasma Critical High - 150 sec Units Fibrinogen 60 - mg/dl INR (International Normalizing
More informationSara K. Vesely, James N. George, Bernhard Lämmle, Jan-Dirk Studt, Lorenzo Alberio, Mayez A. El-Harake, and Gary E. Raskob
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS ADAMTS13 activity in thrombotic thrombocytopenic purpura hemolytic uremic syndrome: relation to presenting features and clinical outcomes in
More informationA 60 year old woman with altered mental status and thrombotic microangiopathy. Josh Veatch
A 60 year old woman with altered mental status and thrombotic microangiopathy Josh Veatch Previously healthy 60 year old woman 2 3 months of fatigue following a URI, transient episodes being out of it
More informationThrombotic thrombocytopenic purpura: 2008 Update
MEDICAL GRAND ROUNDS CME CREDIT MARK A. CROWTHER, MD Director, Division of Hematology, McMaster University, Hamilton, Ontario, Canada JAMES N. GEORGE, MD Hematology-Oncology Section, Department of Medicine,
More informationDocument Title: Hemostasis: Platelet and Coagulation Disorders. Author(s): Joseph H. Hartmann (University of Michigan), DO 2012
Project: Ghana Emergency Medicine Collaborative Document Title: Hemostasis: Platelet and Coagulation Disorders Author(s): Joseph H. Hartmann (University of Michigan), DO 2012 License: Unless otherwise
More informationTTP and ADAMTS13: When Is Testing Appropriate?
TTP and ADAMTS13: When Is Testing Appropriate? Pier Mannuccio Mannucci and Flora Peyvandi A. Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialities, University
More informationHemostatic System - general information
PLATELET DISORDERS Hemostatic System - general information Normal hemostatic system vessel wall circulating blood platelets blood coagulation and fibrynolysis Bleeding Diathesis inherited or acquired defects
More informationACTIFLUOR ADAMTS13 Activity *
ACTIFLUOR ADAMTS13 Activity * A Fluorescence Resonance Energy Transfer (FRET) assay for measuring ADAMTS13 activity in human plasma REF 812RUO 32 i 2 Cl8 C Sekisui Diagnostics, LLC 500 West Avenue, Stamford,
More informationTMA in HUS and TTP: new insights
TMA in HUS and TTP: new insights Daan Dierickx University Hospitals Leuven, Department of Hematology, Belgium 20th Annual Meeting Belgian Society on Thrombosis and Haemostatis Antwerpen, 22 th November
More informationDr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL
Dr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL CASE HISTORY 4 yrs old previously well boy Born to 2 nd degree consanguinity Fever x 5 days
More informationPaolo Gresele Dipartimento di Medicina, Sezione di Medicina Interna e Cardiovascolare, Università di Perugia
Le sindromi trombotiche microangiopatiche: il ruolo del laboratorio Paolo Gresele Dipartimento di Medicina, Sezione di Medicina Interna e Cardiovascolare, Università di Perugia Microangiopatie trombotiche:
More informationNon-immune acquired haemolytic anaemias. Dr.Maysem
Non-immune acquired haemolytic anaemias Dr.Maysem Causes of Non-immune acquired haemolytic anaemias. Infections Infections can cause haemolysis in a variety of ways: -They may precipitate an acute haemolytic
More informationPlatelet Disorders. By : Saja Al-Oran
Platelet Disorders By : Saja Al-Oran Introduction The platelet arise from the fragmentation of the cytoplasm of megakaryocyte in the bone marrow. circulate in the blood as disc-shaped anucleate particles
More informationHaemostasis & Coagulation disorders Objectives:
Haematology Lec. 1 د.ميسم مؤيد علوش Haemostasis & Coagulation disorders Objectives: - Define haemostasis and what are the major components involved in haemostasis? - How to assess the coagulation status?
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug
More informationThrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular. Genetics
Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular Genetics Helen Liapis, M.D. Senior Consultant Arkana Labs Professor of Pathology & Immunology. retired Washington University School
More informationBleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph
Bleeding Disorders Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph Normal hemostasis The normal hemostatic response involves interactions among: The blood vessel wall (endothelium)
More informationClinical study of 9 patients with acquired thrombotic thrombocytopenic purpura
Journal of Clinical and Experimental Medicine VOL.1,ISS.3,DEC 2017,1-5 ONLINE ISSN: 2523-2835 www.jocem.org PRINT ISSN: 2521-0084 DOI:10.29422/jocem.2017.03.001 Abstract: Clinical study of 9 patients with
More informationSoliris (eculizumab) DRUG.00050
Market DC Soliris (eculizumab) DRUG.00050 Override(s) Prior Authorization Approval Duration 1 year Medications Soliris (eculizumab) APPROVAL CRITERIA Paroxysmal Nocturnal Hemoglobinuria I. Initiation of
More informationAswanth P. Reddy, Ujjwal Gupta, and Jonathan S. Harrison. University of Connecticut, Farmington, Connecticut, USA
CASE REPORT Rituximab in Relapsing acquired Thrombotic Thrombo cytopenic Purpura: Experience and Evidence 1 2 1* Aswanth P. Reddy, Ujjwal Gupta, and Jonathan S. Harrison 1 University of Connecticut, Farmington,
More informationBleeding Disorders: (Hemorrhagic Diatheses) Tests used to evaluate different aspects of hemostasis are the following:
Bleeding Disorders: (Hemorrhagic Diatheses) Excessive bleeding can result from: 1. Increased fragility of vessels. 2. Platelet deficiency or dysfunction. 3. Derangement of coagulation. 4. Combinations
More informationBleeding Disorders.2 MS Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD
Bleeding Disorders.2 MS4.25.02.2019 Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD Email: abdalla.awidi@gmail.com Case 6: GT 18 yr old female was admitted with pallor, abdominal pain and gum
More informationDisseminated Intravascular Coagulation (DIC) Seminar. Ron Kopilov 4 th year Medical Student, Tel Aviv University Internal Medicine A 8.3.
Disseminated Intravascular Coagulation (DIC) Seminar Ron Kopilov 4 th year Medical Student, Tel Aviv University Internal Medicine A 8.3.2012 1 Our plan: Understand the pathophysiology Identify risk factors
More informationPresentation Outline. Disease Background Previous research on platelet recovery rate Goal of our study Methods Results Limitations Conclusions
Platelet Recovery Rate at Day 5 of Therapeutic Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura Can Aid in Identifying Risk of Disease Exacerbation Suzanne Zhou, Yara A. Park, Marian A.
More informationHUS and TTP Testing. Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI
HUS and TTP Testing Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI Disclosures Relevant Financial Relationships Consultant: Ablynx, Bayer, CSL Behring,
More information1) unexplained microangiopathic hemolytic anemia (Coombs negative anemia),
Ravi Sarode, MD Consensus Process The TTP-CC subcommittee developed 7 key questions Sent to the 7 speakers for electronic voting in Yes or No format Will be published in JCA soon Q.1 Untreated TTP carries
More informationCurrent understanding of the pathophysiology of thrombotic thrombocytopenic purpura
J Clin Pathol 2000;53:497 501 497 Haemostasis Research Unit, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK S L Allford S J Machin Correspondence to: Dr Allford email: mach263@msn.com
More informationHeme (Bleeding and Coagulopathies) in the ICU
Heme (Bleeding and Coagulopathies) in the ICU General Topics To Discuss Transfusions DIC Thrombocytopenia Liver and renal disease related bleeding Lack of evidence in managing critical illness related
More information1. INSTRUCTIONS 2. DEFINITION OF HUS
CQ_IBK_aHUS_01 / version 25/11/09 European Paediatric Research Group for HUS and related disorders Case questionnaire for diarrhoea negative/vtec (STEC) negative cases acute phase 1. INSTRUCTIONS Please
More informationAccepted Manuscript. No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please. Yeong-Hau H. Lien MD, PhD S (18)
Accepted Manuscript No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please Yeong-Hau H. Lien MD, PhD PII: S0002-9343(18)30965-3 DOI: https://doi.org/10.1016/j.amjmed.2018.10.009 Reference:
More informationRenal failure and thrombocytopaenia? Don t forget TTP/HUS. Jonathan Wala Nephrologist
Renal failure and thrombocytopaenia? Don t forget TTP/HUS Jonathan Wala Nephrologist Thrombotic microangiopathies Disorders characterized by: thrombocytopaenia microangiopathic haemolytic anaemia (MAHA)
More informationFatal Thrombotic Throbmocytopenic Purpura Coexisting with Bacterial Infection: A Case Report
42 Fatal Thrombotic Throbmocytopenic Purpura Coexisting with Bacterial Infection: A Case Report Chih-Yuan Lin and Sheng-Huang Lin Abstract- Thrombotic thrombocytopenic purpura (TTP) has a varied clinical
More informationR. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk
R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy Lindsay Keir Richard
More informationPrimary causes: Complement dysregulation (50% of non-shiga toxin-producing E. coli ) Secondary causes:
General department INTRODUCTION The hemolytic uremic syndrome (HUS): microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury One of the main causes of acute kidney injury in children
More informationRituximab Can Be Combined With Daily Plasma Exchange to Achieve Effective B-Cell Depletion and Clinical Improvement in Acute Autoimmune TTP
Coagulation and Transfusion Medicine / REFRACTORY ACUTE AUTOIMMUNE TTP Rituximab Can Be Combined With Daily Plasma Exchange to Achieve Effective B-Cell Depletion and Clinical Improvement in Acute Autoimmune
More informationThrombotic thrombocytopenic purpura
The Intensive Care Society 2011 Thrombotic thrombocytopenic purpura J Thachil Thrombocytopenia is the most common coagulation problem in intensive care units with an incidence of up to 60% in some studies.
More informationY. Helen Zhang, MD Andy Nguyen, MD 10/28/2012
Y. Helen Zhang, MD Andy Nguyen, MD 10/28/2012 Clinical History Patient: 23-year-old female Clinical course: status-post cholecystectomy, complicated by retained common bile duct stones. Following three
More informationCase Studies. Scleroderma Renal Crisis or Thrombotic Thrombocytopenic Purpura: Seeing Through the Masquerade. Patient 1
Scleroderma Renal Crisis or Thrombotic Thrombocytopenic Purpura: Seeing Through the Masquerade Emily Keeler, DO, 1* Gloria Fioravanti, DO, FACP, 1 Bensson Samuel, MD, PG Dip, 1 Santo Longo, MD 2 Lab Med
More informationThere are two main causes of a low platelet count
Thrombocytopenia Thrombocytopenia is a condition in which a person's blood has an unusually low level of platelets Platelets, also called thrombocytes, are found in a person's blood along with red blood
More informationmonoclonal gammopathy of undetermin Citation Rheumatology international, 33(1),
NAOSITE: Nagasaki University's Ac Title Author(s) Renal thrombotic microangiopathies/ in a patient with primary Sjögren's monoclonal gammopathy of undetermin Koga, Tomohiro; Yamasaki, Satoshi; Atsushi;
More informationClinical Presentation and Follow-up of Eighteen Patients with Thrombotic Thrombocytopenic Purpura Received in: March 2007 Accepted in: 14/1/2010
Clinical Presentation and Follow-up of Eighteen Patients with Thrombotic Thrombocytopenic Purpura Received in: March 2007 Accepted in: 14/1/2010 Dr. Ahmed Khudair Yaseen Elmeshhedany * Dr. Ahmed Abdulmajeed
More informationA 36 year old previously healthy female develops fever and ruising
Renal vascular diseases CPC G.A. Appel MD M.B. Stokes MD Case 1 A 36 year old previously healthy female develops fever and bruising. She goes to her LMD and CBC shows plats 15 K, Hct 28%, normal PT and
More informationApproach To A Bleeding Patient
ABDUL MAJEED, RAHUL RAJEEV REVIEW ARTICLE INTRODUCTION Hemostasis is the process of forming clots in the walls of damaged blood vessels and preventing blood loss while maintaining blood in a fluid state
More informationTTP, Sickle Cell Disease, and the role of von Willebrand factor
TTP, Sickle Cell Disease, and the role of von Willebrand factor José A. López Puget Sound Blood Center University of Washington Seattle, WA Disclosures No conflicts to disclose. Thrombotic Thrombocytopenic
More informationPostoperative Thrombotic Thrombocytopenic Purpura After Open Heart Operations
Postoperative Thrombotic Thrombocytopenic Purpura After Open Heart Operations Darin J. Saltzman, MD, PhD, Jae C. Chang, MD, Juan C. Jimenez, MD, John G. Carson, MD, Amir Abolhoda, MD, Richard S. Newman,
More informationAABB 2003 ANNUAL MEETING AWARD LECTURES
Blackwell Science, LtdOxford, UKTRFTransfusion0041-11322004 American Association of Blood BanksSeptember 200444913841392Original ArticleTHE OKLAHOMA TTP-HUS REGISTRYGEORGE AABB 2003 ANNUAL MEETING AWARD
More informationA Rational Approach to Evaluation of Thrombotic Microangiopathy
A Rational Approach to Evaluation of Thrombotic Microangiopathy An Algorithmic Approach C. Christopher Hook, MD for the Complement Alternative Pathway Thrombotic Micro- Angiopathy (CAP-TMA) Disease-Oriented
More informationVon Willebrand Disease. Alison Street Malaysia April 2010
Von Willebrand Disease Alison Street Malaysia April 2010 Physiology of VWF OUTLINE Clinical presentation of VWD Classification of VWD with emphases on Type 1, 2B and 2N disease Testing for VWD Treatment
More informationAnemia (3).ms4.25.Oct.15 Hemolytic Anemia. Abdallah Abbadi
Anemia (3).ms4.25.Oct.15 Hemolytic Anemia Abdallah Abbadi Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k, retics 12%, LDH
More informationHematologic Disorders. Assistant professor of anesthesia
Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's
More informationOncologic Emergencies. Angelina The, MD Lynn Cancer Institute August 30, 2016
Oncologic Emergencies { Angelina The, MD Lynn Cancer Institute August 30, 2016 What constitutes an oncologic emergency? Complications arising from Cancer Paraneoplastic syndrome Treatment of cancer Requires
More informationINHERITED COAGULOPATHY
Disorder Etiology Pathophysiology and Presentation Lab Findings and Diagnosis Treatment INHERITED COAGULOPATHY HEMOPHILIA A and B Hemophilia A: deficiency in XIII (85%) Hemophilia B: deficiency in IX (15%)
More informationACQUIRED COAGULATION ABNORMALITIES
ACQUIRED COAGULATION ABNORMALITIES ACQUIRED COAGULATION ABNORMALITIES - causes 1. Liver disease 2. Vitamin K deficiency 3. Increased consumption of the clotting factors (disseminated intravascular coagulation
More informationAnemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh
Anemia (3).ms4.26.2.18 Hemolytic Anemia Abdallah Abbadi Feras Fararjeh Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k,
More informationLong-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab
Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab Jens Marcus Chemnitz, Jens Uener, Michael Hallek, Christof Scheid To cite this version: Jens Marcus Chemnitz,
More informationHaemorrhagic Disorders. Dr. Bashar Department of Pathology Mosul Medical College
Haemorrhagic Disorders Dr. Bashar Department of Pathology Mosul Medical College Hemorrhagic Disorders These include Disorders of platelets. Disorders of blood vessels. Disorders of coagulation & fibrinolysis.
More informationTHE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES
THE MULTIPLE FACETS OF THROMBOTIC MICROANGIOPATHIES Summary of Presentations from the Alexion-Sponsored Symposium, held at the 19 th EHA Congress, Milan, Italy, on 12 th June 2014 Chairperson Pier Mannuccio
More informationA 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis).
A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis). He was found to have severe kidney injury requiring
More informationSchematic Of Heparin Induced Thrombocytopenia Platelet Count
Schematic Of Heparin Induced Thrombocytopenia Platelet Count Normal IgG and IgG2 differentially inhibit HIT antibody-dependent platelet activation that platelet counts were lower in FcγRIIA 131RR patients
More informationDr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN
Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN The student should be able:» To identify the mechanism of homeostasis and the role of vessels, platelets
More informationTopics of today lectures: Hemostasis
Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms of hemostasis - Vascular contraction - Platelets plug - Blood coagulation (clotting) - Structure and functions of platelets - Blood
More informationMayo Clin Proc, November 2001, Vol 76 TTP and HUS 1155 plasma samples from some patients with TTP have identified unusually large multimeric forms of
1154 Concise Review for Clinicians Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome MICHELLE A. ELLIOTT, MD, AND WILLIAM L. NICHOLS, MD Thrombotic thrombocytopenic purpura (TTP) and hemolytic
More informationAcquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan
Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan Masanori Matsumoto 1, Charles L. Bennett 2, Ayami Isonishi 1, Zaina Qureshi 2, Yuji Hori 1,
More informationThe New England Journal of Medicine VON WILLEBRAND FACTOR CLEAVING PROTEASE IN THROMBOTIC THROMBOCYTOPENIC PURPURA AND THE HEMOLYTIC UREMIC SYNDROME
VON WILLEBRAND FACTOR CLEAVING PROTEASE IN THROMBOTIC THROMBOCYTOPENIC PURPURA AND THE HEMOLYTIC UREMIC SYNDROME MIHA FURLAN, PH.D., RODOLFO ROBLES, MIRIAM GALBUSERA, SC.D., GIUSEPPE REMUZZI, M.D., PAUL
More informationPLASMA EXCHANGE J MANION NEPEAN HOSPITAL
PLASMA EXCHANGE J MANION NEPEAN HOSPITAL PLASMA The fluid portion of blood Normally approx 5% body weight or 3.5L in 70kg male Clots on standing unless anticoagulated Common plasma proteins are albumin,
More informationUNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.
UNIT VI Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav Hemostasis: Prevention of Blood Loss Vascular constriction Formation of a platelet plug Formation of a blood
More informationUntying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome
REVIEW Untying the Knot of Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Han-Mou Tsai, MD imah Hematology Associates, New Hyde Park, NY. ABSTRACT Patients presenting with microangiopathic
More informationThrombotic Microangiopathies
Thrombotic Microangiopathies ASH/San Antonio Breast Cancer Symposium Review James N. George March 14, 2015 Thrombotic Microangiopathies (TMA): Everything you need to know from 5 patient stories Thrombotic
More informationSpecialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus)
Specialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus) Document Author: Assistant Director for Evidence, Evaluation and Effectiveness Executive Lead: Medical Director
More informationThis slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion
This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion Topics of today lectures: Hemostasis Meaning of hemostasis Mechanisms
More information78 The Power of Peripheral Blood Smears-Apparent Diagnostic Clues (Part 1) Gene Gulati PhD, SH(ASCP)
78 The Power of Peripheral Blood Smears-Apparent Diagnostic Clues (Part 1) Gene Gulati PhD, SH(ASCP) 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe, Ste. 1600 Chicago,
More informationAcute Immune Thrombocytopenic Purpura (ITP) in Childhood
Acute Immune Thrombocytopenic Purpura (ITP) in Childhood Guideline developed by Robert Saylors, MD, in collaboration with the ANGELS team. Last reviewed by Robert Saylors, MD September 22, 2016. Key Points
More information